X

Trial Profile

ALERT: A phase II study of alternating eribulin and hormonal therapy in pre-treated ER+ve breast cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms ALERT

Most Recent Events

01 Jul 2024 Results investigating ctDNA dynamics during alternating cycles of chemotherapy and hormonal treatment in pre-treated patients with oestrogen receptor-positive metastatic breast cancer, published in the Breast Cancer Research and Treatment
19 Sep 2018 Status changed from recruiting to discontinued due to slow patient recruitment.
14 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com